Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Withdrawn before enrolling · Phase 1

Conditions studied: Leukemia, Myeloid, Chronic

In brief

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

Key facts

Study ID

NCT00732186

Run by

Bristol-Myers Squibb

People needed

0

Starts

2009-08-01

Expected to finish

2011-02-01

Last updated by the study team

2016-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ph+ CML on dasatinib therapy
• Loss of cytogenetic or molecular response while on dasatinib therapy
• On stable dose of dasatinib for a minimum of 12 weeks and with < 14 day interruption of treatment

You may not qualify if…

• Blast crisis CML
• Autoimmune disease
• Uncontrolled or significant cardiovascular disease

Where it is running

• The University Of Texas, M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.